Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.

[1]  P. Workman,et al.  Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. , 1992, International journal of radiation oncology, biology, physics.

[2]  G. Adams,et al.  Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice. , 1991, International journal of radiation oncology, biology, physics.

[3]  M. Lemmon,et al.  Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. , 1990, Cancer research.

[4]  G. Adams,et al.  Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. , 1990, Radiation research.

[5]  G. Adams,et al.  Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. , 1990, Journal of medicinal chemistry.

[6]  G. Adams,et al.  The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation. , 1990, British Journal of Cancer.

[7]  G. Adams,et al.  Bioreductive drugs and the selective induction of tumour hypoxia. , 1990, British Journal of Cancer.

[8]  H. Hansen,et al.  In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung. , 1989, European journal of cancer & clinical oncology.

[9]  G. Adams,et al.  Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. , 1989, International journal of radiation biology.

[10]  M. Lemmon,et al.  SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. , 1986, International journal of radiation oncology, biology, physics.

[11]  R. Hill,et al.  Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069. , 1986, British Journal of Cancer.

[12]  G. Adams,et al.  Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. , 1984, British Journal of Cancer.

[13]  I. Smith,et al.  Chemotherapy of human breast-carcinoma xenografts. , 1980, British Journal of Cancer.

[14]  G. Steel,et al.  The therapeutic response of three human tumor lines maintained in immune-suppressed mice. , 1975, Cancer research.

[15]  A. Rauth,et al.  An in vitro assay to measure the viability of KHT tumor cells not previously exposed to culture conditions. , 1974, Radiation research.